•   George Lundberg, MD

    Written for oncology healthcare professionals, this article from the American Journal of Hematology covers the best new therapies for chronic myelomonocytic leukemia in 2022.

    .

  •   George Lundberg, MD

    Written for oncology healthcare professionals, this article from the ASCO Educational Book covers targeted therapies and immunotherapies that are now available to improve the prospects of people with acute myeloid leukemia.

    .

  •   George Lundberg, MD

    Published by Targeted Therapies in Oncology for healthcare professionals, this article outlines how novel targeted therapies have largely replaced chemotherapy and prolonged life greatly for people with chronic lymphocytic leukemia (CLL).

    .

  •   George Lundberg, MD

    Presented by Cancer Therapy Advisor, this collection of stories covers new developments in lymphoma treatment that were presented at the 2022 annual meeting of the American Society of Clinical Oncology.

    .

  •   George Lundberg, MD

    Read about personalized and targeted treatments for many types of lymphoma in this scientific review paper written for medical and research professionals and published in the Journal of Clinical Medicine.

    .

    .

  •   George Lundberg, MD

    According to this Newswise press release from Michigan Medicine – University of Michigan, the U.S. Food and Drug Administration (FDA) has approved the drug zanubrutinib to treat marginal zone lymphoma in some patients, based in part on results from a clinical trial led by researchers at University of Michigan Medical School that demonstrated an 80% response rate.

    .

  •  

    How an Expert Would Manage His Own Advanced Prostate Cancer

    With: Marc B. Garnick, MD

    When facing a new cancer diagnosis, some people ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George asks Marc B. Garnick, MD, how he would handle his own advanced prostate cancer. Dr. Garnick is the Gorman Brothers Professor of Medicine at Harvard Medical School (HMS) and Beth Israel Deaconess Medical Center in Boston, MA. He is also… Read more »

  •   George Lundberg, MD

    In a remarkable new study, covered in this article from The ASCO Post, 100% of 14 previously untreated patients with mismatch repair-deficient rectal cancer had complete responses—that is, no more signs of their cancer—after treatment with the checkpoint-inhibitor drug dostarlimab (brand name Jemperli) in a phase 2 clinical trial.

    .

  •   George Lundberg, MD

    Written for physicians and healthcare professionals, Medscape provides this trustworthy, encyclopedic resource for treating and managing metastatic colorectal cancer.

    .

  •   George Lundberg, MD


    This scientific research paper from Critical Reviews in Oncology/Hematology discusses current options for treatments known as immune checkpoint inhibitors for people with advanced colorectal cancer.

    .